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ABSTRACT
Background. Nearly half of patients with perihilar
cholangiocarcinoma (PHC) have incurable tumors at
laparotomy. Staging laparoscopy (SL) potentially detects
metastases or locally advanced disease, thereby avoiding
unnecessary laparotomy. However, the diagnostic yield of
SL has decreased with improved imaging in recent years.
Objective. The aim of this study was to identify predictors
for detecting metastasized or locally advanced PHC at SL
and to develop a risk score to select patients who may
benefit most from this procedure.
Methods. Data of patients with potentially resectable PHC
who underwent SL between 2000 and 2015 in our center
were retrospectively analyzed. Multivariable logistic
regression analysis was used to identify independent pre-
dictors and to develop a preoperative risk score.
Results. Unresectable PHC was detected in 41 of 273
patients undergoing SL (yield 15 %). Overall sensitivity of
SL was 30 %, with highest sensitivity for detecting peri-
toneal metastases (73 %). Preoperative imaging factors that
were independently associated with unresectability at SL
were tumor size C4.5 cm, bilateral portal vein
involvement, suspected lymph node metastases, and sus-
pected (extra)hepatic metastases on imaging without the
possibility of diagnosis by percutaneous- or endoscopic
ultrasound-guided biopsy. The derived preoperative risk
score showed good discrimination to predict unresectabil-
ity (area under the curve 0.77, 95 % confidence interval
0.68–0.86) and identified three subgroups with a predicted
low-risk of 7 % (N = 203 patients), intermediate-risk of
21 % (N = 39), and high-risk of 58 % (N = 31).
Conclusions. A selective approach for SL in PHC is rec-
ommended since the overall yield is low. The proposed
preoperative risk score is useful in selecting patients for
SL.
Perihilar cholangiocarcinoma (PHC) is a rare disease
with a dismal prognosis for which radical resection remains
the only curative treatment.1 Unfortunately, nearly half of
patients subjected to laparotomy have unresectable tumors,
despite extensive preoperative radiological staging.2,3
Staging laparoscopy (SL) in addition to imaging prior to
exploratory laparotomy may detect small liver metastases
or peritoneal metastases, thereby avoiding unnecessary
laparotomy. However, the true additional diagnostic value
of this procedure remains unclear, with varying results
reported in the literature.4 Currently, the routine use of SL
in preoperative staging of PHC is being questioned as the
majority of studies from recent years have shown a diag-
nostic yield below 20 % and a sensitivity to detect
unresectable disease lower than 60 %.5–9
As the routine use of SL in PHC patients does not seem
justified, a selective approach to identify patients who may
benefit most from this procedure seems warranted.5 There
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is currently no evidence for adequate selection criteria for
SL in PHC patients as most studies are hampered by small
sample size, resulting in low predictive power. The aim of
this study was therefore to identify predictors of unre-
sectable disease at SL and develop a preoperative risk score
in a large cohort of PHC patients treated in a single center
specializing in the management of PHC.
METHODS
Study Population and Selection
Consecutive patients with suspected PHC10 who were
seen at the Academic Medical Center (AMC) in Amster-
dam between May 2000 and July 2015 were identified from
a prospectively maintained database. Exclusion criteria
were SL for gallbladder carcinoma, and distal or intra-
hepatic cholangiocarcinoma.
All patients and radiological scans were discussed in a
multidisciplinary, hepatopancreatobiliary (HPB) team
meeting. In the event of suspected distant lymph node or
organ metastases, percutaneous- or endoscopic ultrasound
(EUS)-guided biopsy was attempted in order to confirm
metastatic disease. When tumors were considered poten-
tially resectable, SL was planned early in the preoperative
workup in all patients with Bismuth–Corlette (BC) type 3–4
tumors. Laparoscopy for BC type 1–2 tumors was conducted
more selectively according to the surgeon’s preference.
Laparoscopy was also performed in the event of suspicious
metastatic lesions on imaging for which diagnosis by per-
cutaneous- or EUS-guided biopsy was not feasible or when
pathological results of biopsies were inconclusive with
persistent suspicion of metastatic disease.
Staging Laparoscopy (SL) and Exploratory Laparotomy
SL was carried out by the HPB surgical fellow or sur-
geon and included inspection of the liver and gallbladder
surface, peritoneal cavity, and hepatoduodenal liga-
ment.5,11 Lymph node sampling was not performed
routinely, but only for enlarged or suspicious lymph nodes.
Furthermore, the lesser omentum was not routinely opened,
but if done so, the common hepatic artery was inspected
along its course, in search of suspicious lymph nodes.
Laparoscopic ultrasound (LUS) was only performed in four
patients within the study period.
Patients were scheduled for exploratory laparotomy
when no metastases or locally advanced tumors were found
at SL, when any new imaging did not show disease pro-
gression, and if the patient remained fit to undergo surgery.
At laparotomy, the abdomen was inspected for any signs of
incurable disease, such as peritoneal deposits, liver
metastases, lymph node involvement beyond the
hepatoduodenal ligament (N2), or locally advanced dis-
ease. Tumors were considered locally advanced if they
invaded surrounding organs or when excessive vascular or
biliary involvement precluded an R0 or R1 resection and
only R2 resection was possible. Portal vein reconstructions
were performed if necessary and technically feasible. All
suspicious lesions and lymph nodes were biopsied and
analyzed by frozen-section microscopic examination.
Definition of Potential Risk Factors
Study variables included clinical variables [jaundice,
carbohydrate antigen (CA) 19-9] and radiological param-
eters that were retrospectively rereviewed on available
computed tomography (CT) and magnetic resonance
imaging (MRI) scans by an experienced staff radiologist
(CYN) who was blinded to the outcome of SL.
Radiological parameters included BC classification,
tumor size, vascular involvement, lobar atrophy, suspected
lymph node metastases, and other suspicious metastatic
lesions (intrahepatic, peritoneal). Suspicious lymph nodes
were larger than 10 mm in short-axis diameter, had irreg-
ular border, or showed central necrosis and were
categorized as perihilar (N1) or beyond the hepatoduodenal
ligament (N2).10,12 Vascular involvement was defined as
more than 180 degrees circumferential tumor contact or as
clear distortion, narrowing or occlusion of the portal
venous system and/or (branches of) hepatic artery.13 Lobar
atrophy was defined as a small, hypoperfused lobe with
crowding of dilated intrahepatic bile ducts. To avoid mis-
interpreting intrahepatic cholangiocarcinoma as PHC, we
adhered to previously published anatomical landmarks.14
Statistical Analysis
The diagnostic accuracy of SL was expressed as the
yield and sensitivity to detect incurable disease. The yield
and sensitivity were calculated by dividing the total num-
ber of avoided laparotomies by the total number of
laparoscopies and all patients with unresectable disease,
respectively.
Logistic regression analysis was used to identify pre-
dictors of unresectable disease at SL. All study variables
with a p value\ 0.100 in univariable analysis were sub-
sequently entered in multivariable analysis. A cut-off for
tumor size was used in these analyses and determined at the
highest sensitivity and specificity. A standard approach was
then used to develop a risk score.15 Independent predictors
(p\ 0.05 in multivariable analysis) were selected and
regression coefficients of these predictors were transformed
into simple points to develop the risk score. The number of
points assigned to each predictor equaled its regression
coefficient in multivariable analysis divided by the
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predictor with the smallest absolute number of points, and
rounded to the nearest whole number. Predicted risks were
then calculated for each patient in the study cohort by
applying total point scores to the logistic regression for-
mula. Risk score tertiles were used to categorize patients
into low-risk, intermediate-risk, and high-risk groups based
on the predicted chance of finding metastases or locally
advanced disease at SL.
Predictive accuracy (discrimination) of the risk score
was assessed using area under the curve (AUC) analysis
with 95 % confidence intervals (CIs). The agreement
between predicted and observed unresectability (calibra-
tion) was assessed using the Hosmer–Lemeshow goodness-
of-fit test, with a significant outcome (p\ 0.05) indicating
a lack of fit. Missing data were rare and were handled with
complete case analysis. All analyses were performed using
IBM SPSS Statistics version 22.0 (IBM Corporation,
Armonk, NY, USA) and R Version 3.1.2 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Patient Demographics and Imaging
A total of 656 patients with suspected PHC were iden-
tified within the study period. After multidisciplinary team
discussion, 348 tumors were found to be potentially
resectable and 273 patients underwent SL (Fig. 1). Preop-
erative staging was performed with ultrasound, CT in most
patients (97 %), and more selectively with MRI (38 %) and
positron emission tomography (PET; 22 %). Patient char-
acteristics are presented in Table 1. Seventy-five patients
were directly scheduled for exploratory laparotomy (elec-
tronic supplementary Table).
Surgical Findings
Inoperable tumors were found during SL in 41 patients,
resulting in a yield of 15 % (95 % CI 11–19). Lesions that
were mainly detected were peritoneal and liver metastases.
Twenty-nine patients who were considered resectable at SL
did not undergo laparotomy (Fig. 1). After a median of 41
days (range 3–156), exploratory laparotomy was performed
in 203 patients and showed unresectable disease in 83
patients (41 %), mainly because of lymph node metastases
and locally advanced tumors that were not apparent on
imaging or during SL (Fig. 1). SL correctly identified 41 of
136 patients with unresectable PHC, resulting in an overall
sensitivity of 30 % (95 % CI 22–38). Highest sensitivity
was found for peritoneal metastases (27/37, 73 %), while
sensitivity for detecting liver metastases was 39 % (9/23).
Locally advanced tumors (8/55, 15 %) or lymph node








Yield            = 41/273 = 15%






























Initially unresectable     N = 308
No laparotomy                  N = 29
Laparotomy without SL N = 75
Unresectable at SL           N = 41
No resection                     N = 83
FIG. 1 Outcomes of patients with suspected perihilar cholangiocarcinoma undergoing staging laparoscopy and exploratory laparotomy at the
Academic Medical Center between 2000 and 2015. SL staging laparoscopy
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44 positive N2 lymph nodes that were found at laparotomy,
29 were located alongside the common hepatic artery.
Complications after SL occurred in eight patients (3 %)
and were all minor (Clavien–Dindo grade I–II) and inclu-
ded urinary retention (N = 3), pneumonia (N = 1), pain
requiring prolonged hospital stay (N = 1), PTC drain dis-
location (N = 1), and fever requiring antibiotics (N = 2).
Complications after exploratory laparotomy occurred in 27
patients (33 %) with unresectable disease, and included 10
major complications (including one death). Median hos-
pital stay for SL was 3 days (range 1–9), including the day
of admission.
Preoperative Predictors of Unresectable Tumors at SL
Univariable and multivariable analysis of predictors for
detecting metastasized or locally advanced PHC at SL are
shown in Table 2. Independent predictors (p\ 0.05 in
multivariable analysis) that were identified were tumor size
(C4.5 cm), portal vein involvement (bilateral or main
stem), suspected metastases in N2 lymph nodes, and sus-
pected (extra)hepatic metastases. No association was found
for proximal extent of bile duct involvement (BC
classification).
There was no difference in the yield of SL in patients
who underwent MRI (16/103, 15.5 %) compared with
those who did not undergo MRI (25/170, 14.8 %).
Preoperative Risk Score
The derived preoperative risk score to predict detection of
metastasized or locally advanced PHC at SL is presented in
Table 3. The sum of the risk score ranges between 0 and 5
points, and predicted risks for each point score are presented
in Table 4. The predicted risk was 7.2 % in the low-risk
tertile (0 points, N = 203 patients), 21.3 % in the interme-
diate-risk tertile (1 point, N = 39), and 58.0 % (range
48.5–91.9 %) in the high-risk tertile (C2 points, N = 31).
Predictive performance of the preoperative risk score
was well, with an AUC of 0.77 (95 % CI 0.68–0.86) and
excellent calibration was observed (Hosmer–Lemeshow
test p = 0.995). Predictive accuracy remained good after
categorizing patients into low-risk, intermediate-risk, and
high-risk groups (AUC 0.77, 95 % CI 0.68–0.86).
DISCUSSION
This is the largest study reporting on the use of SL in
PHC. In 273 consecutive patients, a relatively low yield
(15 %) and overall sensitivity (30 %) of SL were found to
detect unresectable PHC. Several independent risk factors
were identified that accurately predicted detection of
metastases or locally advanced tumors. A preoperative risk
score was developed that showed good discrimination to
predict unresectable PHC at SL.
Few reports have studied the additional role of laparo-
scopy in preoperative staging of PHC, with varying
results.6,9,16–18 Remarkably, until now only one study was
able to identify any predictors for a positive yield.18 In that
study, a significantly higher yield was found for tumors
classified as T2 and T3, rather than T1, according to the
Blumgart staging system. This observation was not con-
firmed in a recent study including 100 patients, but re-
evaluation of scans and T staging had been performed in
only 38 patients in that cohort.9 Notably, only one of three
criteria of the Blumgart system (i.e. PV involvement) was
associated with unresectability at SL in our analysis.
However, the Blumgart staging system was originally
developed for predicting resectability in a complete cohort
of patients with PHC, and may therefore be less applicable
for the decision to perform SL. Variables that were iden-
tified as independent predictors in our study and that were
included in the risk score were tumor size of 4.5 cm or
more, bilateral PV involvement, suspicious lymph node
metastases, and suspicious (extra)hepatic metastases on
imaging. Suspected metastases involved lesions in which it
was not possible to obtain histology by percutaneous
approach or when there was an inconclusive biopsy in spite
of persistent suspicion. The extent of bile duct involvement
was not associated with unresectability at SL, therefore
TABLE 1 Baseline characteristics of the study cohort
Patients (n = 273)
Age, years [mean (SD)] 65 (11)
Jaundice at presentation 235 (86.1)




US duplex 73 (26.7)
PET 61 (22.3)








Left or right duct 5 (1.8)
Data are expressed as number of patients (%), unless stated otherwise
SD standard deviation, CA19-9 carbohydrate antigen 19-9, CT com-
puted tomography, MRI magnetic resonance imaging, US ultrasound,
PET positron emission tomography
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selecting patients for SL based on the BC classification
does not seem justified.
In this study, SL had the highest sensitivity for detecting
peritoneal metastases, whereas sensitivity for liver metas-
tases, locally advanced tumors, and lymph node metastases
was poor. A higher incidence of peritoneal and liver
metastases was noted in large tumors and tumors with
bilateral PV involvement compared with those without
these criteria. In addition, among patients in whom N2
lymph node metastases were suspected on preoperative
imaging, a substantial proportion had peritoneal metastases
at SL. The reasons for missed superficial liver metastases in
this study are not entirely clear as most lesions at laparo-
tomy were located in the anterior liver segments and
therefore could have potentially been detected at SL.
TABLE 2 Univariable and multivariable analysis of risk factors for detecting unresectable perihilar cholangiocarcinoma at staging laparoscopy
Variable Patients Univariable analysis Multivariable analysis
[n (%)] OR (95 % CI) p value OR (95 % CI) p value
Jaundice at presentation 235 (86.1) 1.6 (0.5–4.7) 0.407 –
CA19-9 – 1.0 (1.0–1.0) 0.764 –
Bismuth–Corlette type –
I 12 (4.4) Reference
II 20 (7.3) 1.7 (0.3–10.3) 0.583
IIIa 112 (41.0) 0.7 (0.1–3.3) 0.612
IIIb 60 (22.0) 0.6 (0.1–3.2) 0.507
IV 64 (23.4) 1.3 (0.3–6.5) 0.771
Left or right duct 5 (1.8) 3.3 (0.3–34.8) 0.315
Tumor size, cm
\4.5 248 (90.8) Reference
C4.5 25 (9.2) 3.8 (1.6–9.3) 0.004 4.1 (1.4–11.8) 0.008
Portal vein involvement
None 151 (55.3) Reference
Unilateral 98 (35.9) 1.1 (0.5–2.4) 0.754 1.1 (0.5–2.7) 0.830
Bilateral or main stem 24 (8.8) 5.3 (2.0–13.6) 0.001 3.9 (1.3–12.2) 0.021
Hepatic artery involvement
None 175 (64.1) Reference
Unilateral 89 (32.6) 1.5 (0.7–3.1) 0.279 1.3 (0.5–3.0) 0.564
Bilateral or main stem 9 (3.3) 9.2 (2.3–36.9) 0.002 4.2 (0.7–23.4) 0.105
Suspected lymph node metastases
None 181 (66.3) Reference
N1 73 (26.7) 1.2 (0.5–2.7) 0.645 0.6 (0.2–1.7) 0.345
N2 19 (7.0) 8.5 (3.1–23.2) \0.001 4.9 (1.4–16.6) 0.012
Suspected (extra)hepatic metastases 22 (8.1) 9.2 (3.7–23.2) \0.001 9.3 (2.9–30.4) \0.001
Lobar atrophy 63 (23.1) 0.8 (0.3–1.8) 0.558 –
Suspected metastases were suspicious metastatic lesions on imaging for which diagnosis by percutaneous biopsy was not feasible or when
pathological results of biopsies were inconclusive with ongoing suspicion of metastases. N2 lymph nodes were located beyond the hepato-
duodenal ligament
OR odds ratio, CI confidence interval, CA19-9 carbohydrate antigen 19-9
TABLE 3 Preoperative risk score to predict unresectable perihilar
cholangiocarcinoma at staging laparoscopy
Variable Classes Points
Tumor size, cm \4.5 0
C4.5 1
Portal vein involvement None or unilateral 0
Bilateral or main stem 1
Suspected lymph node metastasesa None or N1 lymph
nodes
0





a Ongoing suspicion on lymph node or (extra)hepatic metastases after
previous inconclusive/negative biopsy
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The median interval between SL and laparotomy was 41
days and included required time for adequate biliary drai-
nage and/or hypertrophy to occur after portal vein
embolization. Metastases may have developed or may have
grown substantially to become visible in that time, although
PHC is characterized by a rather indolent growth. Ideally, SL
and laparotomy would be performed in a single session in
order to limit hospital admissions and surgical procedures.
However, diagnosis of malignancy is sometimes difficult on
frozen sections and biopsy material may require additional
(immunohistochemical) staining. In addition, many centers
face logistical issues related to anesthetic and operating room
time planning, and prefer to perform SL separately from
laparotomy. Furthermore, early detection of inoperability
allows the timely start of palliative care.
At laparotomy, N2 lymph node metastases were a
common finding precluding resection, of which the
majority were located along the course of the common
hepatic artery. As others confirm the high incidence of
unexpected lymph node metastases at laparotomy,2 a more
extended laparoscopic staging procedure in high-risk
patients is recommended. Instead of only visualizing the
liver surface and peritoneal cavity, routine opening of the
lesser sac, and biopsy of lymph nodes at the anterior side of
the common hepatic artery (lymph node station 8a), is
currently added in these patients in our department. The
incidence of complications following SL was low in this
study and included only minor events. However, 20 %
minor and 12 % major complications (including one death)
were observed following exploratory laparotomy in
patients with unresectable PHC. These findings highlight
the need for accurate preoperative staging.
LUS was only performed in four patients in this study
period as it was previously found to be of limited value in
our center.11 LUS may theoretically be useful in detecting
non-superficial liver metastases or vascular involvement,
but obtaining histological evidence in the latter case might
be difficult without exploration of the liver hilum. Unfor-
tunately, limited data on the additional value of LUS are
available from other studies in the literature.4 In only two
of six studies, the diagnostic yield of SL was increased with
the use of LUS, mainly due to the identification of locally
advanced tumors.16,19
The eventual yield of SL is influenced by the extent of
preoperative imaging. In our cohort, most patients under-
went CT, whereas MRI and PET–CT were only performed
in selected patients. Limited data are available to assume
that the additional use of MRI will increase the yield of
imaging in potentially resectable PHC. Previous studies
have found no differences in the diagnostic accuracy of CT
or MRI for detecting lymph node metastases.20–22
Nonetheless, studies are hampered by their retrospective
design and small sample size. The additional value of
PET–CT was previously investigated at our center, but all
patients had undergone SL in that study.23 It was found that
the yield of PET–CT after staging using CT and laparo-
scopy was disappointing because of the low sensitivity for
detecting distant metastases and comparable detection of
lymph node metastases. However, in a large, prospective
study including patients not undergoing SL, it was shown
that PET–CT had higher accuracy over CT/MRI in the
detection of lymph node metastases and distant metas-
tases.24 Furthermore, in that study it was shown that PET–
CT revealed unsuspected metastases and clarified indeter-
minate lesions. Future studies might compare the use of
PET–CT and SL in the preoperative staging of PHC.
Lastly, EUS is often performed to evaluate suspicious
lymph nodes. Although the results of EUS-guided lymph
node biopsy vary in the literature, this less-invasive tech-
nique seems a preferred step prior to SL;25 however, some
caution may be advised as tumor tract seeding has been
reported.26
The present study has several limitations. The relatively
few unresectable tumors that were detected at SL conse-
quently provided a low number of events for statistical
analysis, which may have led to statistical uncertainty in the
multivariable analysis, as reflected by the relatively wide CIs.
Second, we were unable to perform external validation of the
proposed risk score because of the limited sample size. Future
studies that validate the risk score are therefore desirable.
Third, as this study comprises a cohort of 15 years, the quality
of preoperative imaging varied during the study period and
may have subsequently influenced the assessment of vascular
involvement or metastases in the early years. However, scans
were rereviewed by a specialized radiologist and we also did
not note any changes in the diagnostic yield of SL within the
study period.
CONCLUSIONS
The results from this study support a selective approach to
SL in patients with potentially resectable PHC. The proposed
TABLE 4 Predicted and observed risks according to the risk score
points
Group Point total N Unresectability at SL
Predicted (%) Observed (%)
Low-risk 0 203 7.2 6.4
Intermediate-risk 1 39 21.3 28.2
High-risk 2 21 48.5 47.6
3 9 76.5 66.7
4 1 91.9 100
5 0 NA NA
N number of patients in the study for each point score, NA not
applicable, SL staging laparoscopy
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preoperative risk score can be useful in selecting patients
who may benefit most from this additional staging proce-
dure. Patients in the low-risk group can proceed to
exploratory laparotomy without SL. The use of SL in the
intermediate-risk group is debatable, whereas patients in the
high-risk group are likely to be diagnosed with incurable
disease at SL, thereby avoiding an unnecessary laparotomy.
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